BlueRock Therapeutics has signed agreements with Rune Labs and Emerald Innovations to evaluate digital health technologies for remote patient monitoring in Parkinson's disease clinical trials.
BlueRock Therapeutics is initiating a Phase 3 trial, exPDite-2, for bemdaneprocel, a cell therapy for Parkinson's disease, expected to begin in the first half of 2025.
Bayer's BlueRock Therapeutics initiated a Phase 1 trial of DA01, a cell-based therapy using stem cell-derived dopaminergic neurons, to replenish lost neurons in Parkinson's patients.
BlueRock Therapeutics presented positive 24-month data for its cell therapy, bemdaneprocel, in patients with Parkinson's disease, indicating sustained potential benefits.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.